Alkermes Settles Patent Litigation With Teva Pharmaceuticals Related To Vivitrol (Naltrexone For Extended-release Injectable Suspension). Teva Can Market A Generic Version Of Vivitrol In The US Beginning January 15, 2027
Portfolio Pulse from Benzinga Newsdesk
Alkermes has settled its patent litigation with Teva Pharmaceuticals over Vivitrol. As part of the settlement, Teva can market a generic version of Vivitrol in the US starting January 15, 2027.
August 30, 2023 | 11:12 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alkermes has settled its patent dispute with Teva, allowing Teva to market a generic version of Vivitrol from 2027.
The settlement of the patent litigation removes a potential legal risk for Alkermes. However, the agreement for Teva to market a generic version of Vivitrol from 2027 could potentially impact Alkermes' revenues from that date.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
NEUTRAL IMPACT
Teva Pharmaceuticals has settled its patent dispute with Alkermes and can market a generic version of Vivitrol in the US from 2027.
The settlement of the patent litigation removes a potential legal risk for Teva. The agreement to market a generic version of Vivitrol from 2027 could potentially provide a new revenue stream for Teva from that date.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100